Originally posted by spikefader
View Post
Carl Icahn, the new C.O.B., is shaking things up over there where the inept management is concerned, looking to get a more business-minded C.E.O. with biotech experience, and seeking to improve a somewhat strained relationship with partner, Bristol-Myers Squibb. This is all very positive, in my opinion, and long overdue.
I could be eventually proven wrong, but I believe ImClone will rock again.

SssSss.



Leave a comment: